Discussing the potential of gene therapies for sickle cell disease including Vertex and CRISPR Therapeutics' Casgevy (Exa-cel) and Bluebird bio's Lyfgenia (lovotibeglogene autotemcel)

Executed on:Mar 13, 2025 12:45 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Texas Southwestern Medical CenterEmerius Professor of Pediatrics in the Division of Hematology/Oncology at the University of Texas Southwestern Medical Center in Dallas
40 years experience in the care of pediatric patients with sickle cell disease including participation in 2 NIH:NHLBI funded Comprehensive Sickle Cell Disease Centers.
Current activities specifically include vice chair of NIH:NHLBI DSMB #1 for bone marrow transplantation and other cellular therapies in sickle cell disease and hematology and grant review for participating centers

Interview Goal

On this call we will be discussing the potential of gene therapies for sickle cell disease including Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.